Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-7631 in advanced solid tumors
NCT06381050Phase 1Completed
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- May 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-7631 in solid tumor (advanced stage), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Maximum Tolerated Dose or Maximum Administered Dose at 12 months and Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) at 36 months. Started May 2024; status: completed.
02
Drugs
SHR-7631
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06381050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06381050.